@article{ATM10302,
author = {Katherina-Bernadette Sreter and Marko Jakopovic and Zoran Janevski and Miroslav Samarzija and Paul Zarogoulidis and Ioannis Kioumis and Nikolaos Mparmpetakis and Athanasia Pataka and Konstantinos Zarogoulidis and Theodora Tsiouda and Christoforos Kosmidis and Sofia Mpaka and Haidong Huang and Wolfgang Hohenforst-Schmidt and Charalampos Charalampidis and Nikolaos Machairiotis and Bojan Zaric and Aleksandar Milovancev},
title = {A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?},
journal = {Annals of Translational Medicine},
volume = {4},
number = {9},
year = {2016},
keywords = {},
abstract = {Background: Lung cancer is the leading cause of malignant pleural effusion (MPE). Management of MPEs remains a clinical challenge due to recurrence and poor quality of life. An ideal sclerosing agent has yet to be found. The aim of this cohort pilot study was to evaluate the role of mitoxantrone pleurodesis (MP) as an alternative to talc sclerotherapy for managing MPEs in lung cancer patients.
Methods: A retrospective chart review was conducted on consecutively admitted patients with MPE to the Department of Post-Intensive Care at the Clinic for Respiratory Diseases “Jordanovac”, University Hospital Centre Zagreb, in Croatia.
Results: Of 34 patients with MPE, twenty-one (64.8±9.46 years; 47–84 years) with primary lung carcinoma who received MP (30 mg of mitoxantrone) between December 2003 and February 2009 were included in this study. Chest radiographs taken prior to sclerotherapy and at 1-, 2-, and 3-month follow-up were compared. At the post-sclerotherapy evaluation periods, overall success (OS) rates of MP were 88.2% [17.6%, complete response (CR); 70.6%, partial response (PR)], 53.9% (7.7% CR; 46.2% PR), and 45.5% (PR), respectively. Kaplan-Meier median survival from MP until death was 5.2 months, while that from diagnosis of primary lung cancer was 12.3 months.
Conclusions: MP may be a safe and effective method of managing MPE due to lung cancer. Future randomized controlled studies comparing mitoxantrone and talc pleurodesis in lung cancer patients are warranted to elucidate whether a significant difference exists between these agents. Factors affecting success, survival probability, and quality of life also require further investigation.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10302}
}